Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Medtronic Launches Innovative Insulin Delivery System with Abbott Partnership

Medtronic, a leader in medical technology, has begun the U.S. rollout of its latest insulin pump system, marking a significant advancement in diabetes management technology. The MiniMed 780G insulin pump, now integrated with Abbott's Instinct sensor, represents a groundbreaking collaboration between two industry giants and a departure from Medtronic's traditional approach of pairing its pumps with in-house continuous glucose monitors (CGMs).

NoahAI News12/4/2025

Bristol Myers Squibb Delays Key Alzheimer's Psychosis Trial for Cobenfy Amid Site Irregularities

Bristol Myers Squibb (BMS) has announced a significant delay in the readout of its closely watched ADEPT-2 trial, evaluating the drug Cobenfy for Alzheimer's disease psychosis. The pharmaceutical giant cited "irregularities" in trial execution at some study sites, pushing the expected results to 2026.

NoahAI News12/4/2025

Akura Medical Secures $53M in Series C Funding to Advance Thrombectomy Technology

Akura Medical, a California-based medical device company, has successfully closed a $53 million Series C financing round to accelerate the development of its innovative thrombectomy technologies. The funding, led by Qatar Investment Authority, will support the advancement of Akura's Katana thrombectomy system and NavIQ procedural planning software, both aimed at improving blood clot removal procedures.

NoahAI News12/4/2025

FDA Scales Back Animal Testing Requirements for Certain Antibody Therapies

The U.S. Food and Drug Administration (FDA) has announced plans to reduce or eliminate testing on non-human primates for specific antibody therapies, marking a significant shift in the agency's approach to drug evaluation. This move aligns with the FDA's broader initiative to transition away from animal experiments in favor of more advanced, human-relevant testing methods.

NoahAI News12/4/2025

Cosmo Pharmaceuticals Reveals Promising Phase 3 Results for Male Pattern Hair Loss Treatment

Cosmo Pharmaceuticals has announced groundbreaking results from two phase 3 trials for its topical cream clascoterone, potentially revolutionizing the treatment of male pattern hair loss. The studies, involving 1,465 participants across 50 sites in Europe and the U.S., demonstrated significant improvements in hair growth compared to placebo.

NoahAI News12/4/2025

Capricor's Duchenne Cell Therapy Achieves Breakthrough in Phase 3 Trial, Setting Stage for FDA Approval

Capricor Therapeutics has made a significant leap forward in the treatment of Duchenne muscular dystrophy (DMD) with its cell therapy, deramiocel, achieving remarkable success in a pivotal Phase 3 trial. The results have not only revitalized the company's prospects but also ignited hope for patients suffering from this debilitating genetic disorder.

NoahAI News12/4/2025

Medtronic Reshapes Acute Care and Monitoring Business with Key Appointment

Medtronic, a leading medical technology company, has announced a significant leadership change in its acute care and monitoring business. The move comes as part of a broader restructuring effort within the company, signaling a renewed focus on innovation and growth in this crucial segment.

NoahAI News12/4/2025

AI-Driven M&A Acceleration Expected in Medtech Industry for 2026

The medtech industry is poised for significant growth and transformation in 2026, with artificial intelligence (AI) playing a pivotal role in driving merger and acquisition (M&A) activity. According to a recent outlook report by PitchBook, strategic investors are showing renewed optimism and targeting companies approaching clinical milestones in key areas such as cardiology, orthopedics, and diagnostics.

NoahAI News12/4/2025

FDA Approves Cleveland Diagnostics' Next-Gen Prostate Cancer Test, Potentially Reducing Unnecessary Biopsies

Cleveland Diagnostics has received FDA approval for its novel IsoPSA blood test, designed to improve upon traditional prostate-specific antigen (PSA) screening methods for prostate cancer. The test, which analyzes the structure of protein biomarkers rather than just their concentration, aims to help clinicians better determine whether patients with elevated PSA levels should undergo biopsy procedures.

NoahAI News12/4/2025

Triana Biomedicines Secures $120M Series B for Molecular Glue Degrader Development

Triana Biomedicines has successfully closed a $120 million series B funding round, positioning the company to advance its innovative molecular glue degrader platform into clinical trials. The financing, co-led by Ascenta Capital and Bessemer Venture Partners, brings together a mix of existing and new investors to support Triana's mission of developing novel therapies for difficult-to-treat cancers.

NoahAI News12/4/2025

AI-Powered Chemistry Startup Excelsior Sciences Raises $95M to Revolutionize Small Molecule Discovery

Excelsior Sciences, a New York City-based artificial intelligence (AI) chemistry startup, has secured $95 million in funding to accelerate the discovery and production of small molecules. The company, which spun out of investment firm Deerfield Management, aims to transform the pharmaceutical industry with its innovative "smart bloccs" platform.

NoahAI News12/4/2025

Pharvaris' Oral HAE Treatment Shows Promise in Phase 3 Trial, Enters Competitive Market

Pharvaris, a Netherlands-based biotechnology company, has announced positive results from a Phase 3 trial of its oral medication for hereditary angioedema (HAE), a rare swelling disorder. The drug, deucrictibant, demonstrated significant efficacy in relieving HAE attack symptoms, potentially positioning it as a strong contender in an increasingly competitive market.

NoahAI News12/4/2025

«1...4 5 6...67 »